Nicotine effects and the endogenous opioid system

Journal of Pharmacological Sciences

Volumn 125, Issue 2, 2014, Pages 117-124

  Kishioka, Shiroh ^a   Kiguchi, Norikazu ^a   Kobayashi, Yuka ^a   Saika, Fumihiro ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Antinociception; Nicotine; Opioid system; Physical dependence; 7 nAChR

Indexed keywords

CHOLINERGIC RECEPTOR; CORTICOSTERONE; NEUROTRANSMITTER; NICOTINE; OPIATE; OPIATE PEPTIDE; PROENKEPHALIN; ANALGESIC AGENT; BUNGAROTOXIN RECEPTOR; METENKEPHALIN; NALOXONE; NARCOTIC ANTAGONIST;

ANALGESIA; ANTINOCICEPTION; DRUG DEPENDENCE; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; NEUROPATHIC PAIN; NEUROTRANSMITTER RELEASE; NOCICEPTIVE PAIN; NONHUMAN; PSYCHOLOGICAL ASPECT; REVIEW; TOBACCO DEPENDENCE; WITHDRAWAL SYNDROME; ANIMAL; DRUG EFFECTS; HYPOPHYSIS ADRENAL SYSTEM; PHYSIOLOGY; SECRETION (PROCESS); SPINAL CORD; TOBACCO USE DISORDER;

ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR; ANALGESICS; ANIMALS; ENKEPHALIN, METHIONINE; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; NALOXONE; NARCOTIC ANTAGONISTS; NICOTINE; OPIOID PEPTIDES; PITUITARY-ADRENAL SYSTEM; SPINAL CORD; SUBSTANCE WITHDRAWAL SYNDROME; TOBACCO USE DISORDER;

EID: 84903983214     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.14R03CP     Document Type: Review

References (55)

1. Gotti C, Zoli M, Clementi F. Brain nicotinic acetylcholine receptors: native subtypes and their relevance. Trends Pharmacol Sci. 2006;27:482-491. (Pubitemid 44251225)
2. Jensen AA, Frølund B, Liljefors T, Krogsgaard-Larsen P. Neuronal nicotinic acetylcholine receptors: structural revelations, target identifications, and therapeutic inspirations. J Med Chem. 2005;48:4705-4745. (Pubitemid 41038456)
3. Tripathi HL, Martin BR, Aceto MD. Nicotine-induced antinociception in rats and mice: correlation with nicotine brain levels. J Pharmacol Exp Ther. 1982;221:91-96. (Pubitemid 12156477)
4. Zarrindast MR, Pazouki M, Nassiri-Rad S. Involvement of cholinergic and opioid receptor mechanisms in nicotine-induced antinociception. Pharmacol Toxicol. 1997;81:209-213. (Pubitemid 27475646)
5. Pajusco B, Chiamulera C, Quaglio G, Moro L, Casari R, Amen G, et al. Tobacco addiction and smoking status in heroin addicts under methadone vs. buprenorphine therapy. Int J Environ Res Public Health. 2012;9:932-942
6. Liu S1, Zhou W, Zhang J, Wang Q, Xu J, Gui D. Differences in cigarette smoking behaviors among heroin inhalers versus heroin injectors. Nicotine Tob Res. 2011;13:1023-1028.
7. Kalman D, Morissette SB, George TP. Co-morbidity of smoking in patients with psychiatric and substance use disorders. Am J Addict. 2005;14:106-123. (Pubitemid 40577885)
8. Haass M, Kübler W. Nicotine and sympathetic neurotransmission. Cardiovasc Drugs Ther. 1997;10:657-665.
9. Gudehithlu KP, Duchemin AM, Tejwani GA, Neff NH, Hadjiconstantinou M. Nicotine-induced changes of brain β-endorphin. Neuropeptides. 2012;46:125-131.
10. Boyadjieva NI, Sarkar DK. The secretory response of hypothalamic beta-endorphin neurons to acute and chronic nicotine treatments and following nicotine withdrawal. Life Sci. 1997; 61:PL59-PL66. (Pubitemid 27303943)
11. Houdi AA, Pierzchala K, Marson L, Palkovits M, Van Loon GR. Nicotine-induced alteration in Tyr-Gly-Gly and Met-enkephalin in discrete brain nuclei reflects altered enkephalin neuron activity. Peptides. 1991;12:161-166.
12. Isola R, Zhang H, Tejwani GA, Neff NH, Hadjiconstantinou M. Acute nicotine changes dynorphin and prodynorphin mRNA in the striatum. Psychopharmacology. 2009;201:507-516.
13. Kiguchi N, Maeda T, Tsuruga M, Yamamoto A, Yamamoto C, Ozaki M, et al. Involvement of spinal Met-enkephalin in nicotine-induced antinociception in mice. Brain Res. 2008;1189:70-77. (Pubitemid 351842550)
14. Campbell VC, Taylor RE, Tizabi Y. Antinociceptive effects of alcohol and nicotine: involvement of the opioid system. Brain Res. 2006;1097:71-77. (Pubitemid 44043109)
15. Berrendero F, Mendizábal V, Robledo P, Galeote L, Bilkei-Gorzo A, Zimmer A, et al. Nicotine-induced antinociception, rewarding effects, and physical dependence are decreased in mice lacking the preproenkephalin gene. J Neurosci. 2005;25:1103-1112. (Pubitemid 40268951)
16. Galeote L, Kieffer BL, Maldonado R, Berrendero F. Mu-opioid receptors are involved in the tolerance to nicotine antinociception. J Neurochem. 2006;97:416-423.
17. Biała G, Budzyńska B, Kruk M. Naloxone precipitates nicotine abstinence syndrome and attenuates nicotine-induced antinociception in mice. Pharmacol Rep. 2005;57:755-760.
18. Yamamoto A, Kiguchi N, Kobayashi Y, Maeda T, Ueno K, Yamamoto C, et al. Pharmacological relationship between nicotinic and opioid systems in analgesia and corticosterone elevation. Life Sci. 2011;89:956-961.
19. Bannon AW, Decker MW, Holladay MW, Curzon P, Donnelly- Roberts D, Puttfarcken PS, et al. Broad-spectrum, non-opioid analgesic activity by selective modulation of neuronal nicotinic acetylcholine receptors. Science. 1998;279:77-81. (Pubitemid 28079158)
20. Berrendero F, Kieffer BL, Maldonado R. Attenuation of nicotine-induced antinociception, rewarding effects, and dependence in μ-opioid receptor knock-out mice. J Neurosci. 2002;22:10935-10940. (Pubitemid 36005169)
21. Di Cesare Mannelli L, Zanardelli M, Ghelardini C. Nicotine is a pain reliever in trauma- and chemotherapy-induced neuropathy models. Eur J Pharmacol. 2013;711:87-94.
22. Rashid MH, Ueda H. Neuropathy-specific analgesic action of intrathecal nicotinic agonists and its spinal GABA-mediated mechanism. Brain Res. 2002;953:53-62. (Pubitemid 35217807)
23. Maeda T, Kishioka S. Chapter 13 PPAR and pain. Int Rev Neurobiol. 2009;85:165-177.
24. Kiguchi N, Maeda T, Kobayashi Y, Saika F, Kishioka S. Chapter 14 involvement of inflammatory mediators in neuropathic pain caused by vincristine. Int Rev Neurobiol. 2009;85:179-190.
25. Maeda T, Kiguchi N, Kobayashi Y, Ikuta T, Ozaki M, Kishioka S. Leptin derived from adipocytes in injured peripheral nerves facilitates development of neuropathic pain via macrophage stimulation. Proc Natl Acad Sci U S A. 2009;106: 3076-13081.
26. Kiguchi N, Kobayashi Y, Maeda T, Fukazawa Y, Tohya K, Kimura M, et al. Epigenetic augmentation of the MIP-2/CXCR2 axis through histone H3 acetylation in injured peripheral nerves elicits neuropathic pain. J Pharmacol Exp Ther. 2012;340:577-587.
27. Iwaszkiewicz KS, Schneider JJ, Hua S. Targeting peripheral opioid receptors to promote analgesic and anti-inflammatory actions. Front Pharmacol. 2013;4:132.
28. Schäfer M, Carter L, Stein C. Interleukin 1 b and corticotropin-releasing factor inhibit pain by releasing opioids from immune cells in inflamed tissue. Proc Natl Acad Sci U S A. 1994;91:4219-4223.
29. Cabot PJ, Carter L, Gaiddon C, Zhang Q, Schäfer M, Loeffler JP, et al. Immune cell-derived beta-endorphin. Production, release, and control of inflammatory pain in rats. J Clin Invest. 1997;100:142-148. (Pubitemid 27311252)
30. Cabot PJ, Carter L, Schäfer M, Stein C. Methionine-enkephalin-and Dynorphin A-release from immune cells and control of inflammatory pain. Pain. 2001;93:207-212. (Pubitemid 32763177)
31. Labuz D, Schmidt Y, Schreiter A, Rittner HL, Mousa SA, Machelska H. Immune cell-derived opioids protect against neuropathic pain in mice. J Clin Invest. 2009;119:278-286.
32. Kiguchi N, Kobayashi Y, Maeda T, Tominaga S, Nakamura J, Fukazawa Y, et al. Activation of nicotinic acetylcholine receptors on bone marrow-derived cells relieves neuropathic pain accompanied by peripheral neuroinflammation. Neurochem Int. 2012;61:1212-1219.
33. Mellon RD, Bayer BM. The effects of morphine, nicotine and epibatidine on lymphocyte activity and hypothalamic- pituitary-adrenal axis responses. J Pharmacol Exp Ther. 1999; 288:635-642. (Pubitemid 29119675)
34. Lutfy K, Brown MC, Nerio N, Aimiuwu O, Tran B, Anghel A, et al. Repeated stress alters the ability of nicotine to activate the hypothalamic-pituitary- adrenal axis. J Neurochem. 2006;99: 1321-1327. (Pubitemid 44730088)
35. Armario A. Activation of the hypothalamic-pituitary-adrenal axis by addictive drugs: different pathways, common outcome. Trends Pharmacol Sci. 2010;31:318-325.
36. Abdin MJ, Morioka N, Morita K, Kitayama T, Kitayama S, Nakashima T, et al. Analgesic action of nicotine on tibial nerve transection (TNT)-induced mechanical allodynia through enhancement of the glycinergic inhibitory system in spinal cord. Life Sci. 2006;80:9-16. (Pubitemid 44809291)
37. Damaj MI, Meyer EM, Martin BR. The antinociceptive effects of α7 nicotinic agonists in an acute pain model. Neuropharmacology. 2000;39:2785-2791.
38. Marubio LM, del Mar Arroyo-Jimenez M, Cordero-Erausquin M, Léna C, Le Novère N, de Kerchove d'Exaerde A, et al. Reduced antinociception in mice lacking neuronal nicotinic receptor subunits. Nature. 1999;398:805-810.
39. Smith JS, Schindler AG, Martinelli E, Gustin RM, Bruchas MR, Chavkin C. Stress-induced activation of the dynorphin/k-opioid receptor system in the amygdala potentiates nicotine conditioned place preference. J Neurosci. 2012;32:1488-1495.
40. Childs E1, de Wit H. Effects of acute psychosocial stress on cigarette craving and smoking. Nicotine Tob Res. 2010;12: 449-453.
41. Walsh K, Elliott JC, Shmulewitz D, Aharonovich E, Strous R, Frisch A, et al. Trauma exposure, posttraumatic stress disorder and risk for alcohol, nicotine, and marijuana dependence in Israel. Compr Psychiatry. 2014. In press.
42. Blendy JA, Strasser A, Walters CL, Perkins KA, Patterson F, Berkowitz R, et al. Reduced nicotine reward in obesity: cross-comparison in human and mouse. Psychopharmacology (Berl). 2005;180:306-315. (Pubitemid 40909676)
43. Hughes JR, Gust SW, Skoog K, Keenan RM, Fenwick JW. Symptoms of tobacco withdrawal: a replication and extension. Arch Gen Psychiatry. 1991;48:52-59.
44. Malin DH. Nicotine dependence: studies with a laboratory model. Pharmacol Biochem Behav. 2001;70:551-559. (Pubitemid 34131648)
45. Kishioka S, Nishida S, Fukunaga Y, Yamamoto H. Quantitative properties of plasma corticosterone elevation induced by naloxone-precipitated withdrawal in morphine-dependent rats. Jpn J Pharmacol. 1994;66:257-263. (Pubitemid 24357108)
46. Ueno K, Maeda T, Kiguchi N, Kobayashi Y, Ozaki M, Kishioka S. Availability of serum corticosterone level for quantitative evaluation of morphine withdrawal in mice. Drug Discov Ther. 2011;5:71-75.
47. Martín F, Laorden ML, Milanés MV. Morphine withdrawal regulates phosphorylation of cAMP response element binding protein (CREB) through PKC in the nucleus tractus solitarius-A2 catecholaminergic neurons. J Neurochem. 2009;110:1422-1432.
48. Malin DH, Lake JR, Carter VA, Cunningham JS, Wilson OB. Naloxone precipitates nicotine abstinence syndrome in the rat. Psychopharmacology (Berl). 1993;112:339-342. (Pubitemid 23278298)
49. Ueno K, Kiguchi N, Kobayashi Y, Saika F, Wakida N, Yamamoto C, et al. Possible involvement of endogenous opioid system located downstream of α7 nicotinic acetylcholine receptor in mice with physical dependence on nicotine. J Pharmacol Sci. 2014;124:47-53.
50. Kumar S, Kumar D, Muniyandi M, Soan V, Pandey M, Mishra DK. Poverty does not limit tobacco consumption among tribal populations: evidence from Central India. Asian Pac J Cancer Prev. 2013;14:6195-6196.
51. Maskos U, Molles BE, Pons S, Besson M, Guiard BP, Guilloux JP, et al. Nicotine reinforcement and cognition restored by targeted expression of nicotinic receptors. Nature. 2005;436: 103-107. (Pubitemid 40966193)
52. Benowitz NL. Nicotine addiction. N Engl J Med. 2010;362: 2295-2303.
53. Coe JW, Brooks PR, Vetelino MG, Wirtz MC, Arnold EP, Huang J, et al. Varenicline: an α4β2 nicotinic receptor partial agonist for smoking cessation. J Med Chem. 2005;48:3474-3477. (Pubitemid 40664098)
54. Williams JM, Steinberg MB, Steinberg ML, Gandhi KK, Ulpe R, Foulds J. Varenicline for tobacco dependence: panacea or plight? Expert Opin Pharmacother. 2011;12:1799-1812.
55. Grabus SD, Martin BR, Damaj MI. Nicotine physical dependence in the mouse: Involvement of the α7 nicotinic receptor subtype. Eur J Pharmacol. 2005;515:90-93. (Pubitemid 40779272)